{"id":955781,"date":"2026-04-29T06:33:55","date_gmt":"2026-04-29T10:33:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/"},"modified":"2026-04-29T06:33:55","modified_gmt":"2026-04-29T10:33:55","slug":"teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/","title":{"rendered":"Teva to Acquire\u00a0Emalex\u00a0Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva\u2019s Pivot to Growth Strategy"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>\n          <strong><br \/>\n            <em>Ecopipam, Emalex\u2019s investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations.\u00a0<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li>\n          <strong><br \/>\n            <em>The\u00a0late-stage\u00a0program in\u00a0a\u00a0high-need, specialized\u00a0area of\u00a0neuroscience\u00a0expands\u00a0Teva\u2019s innovative medicines pipeline,\u00a0aligns with commercial strengths and supports both near-\u00a0and\u00a0long-term\u00a0growth.\u00a0<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li>\n          <strong><br \/>\n            <em>Upon closing, Emalex shareholders to receive $700 million in cash with the possibility of up to an additional $200 million in commercial milestone payments, as well as net sales-based royalties, subject to regulatory approval<\/em><br \/>\n          <\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">PARSIPPANY, N.J. and CHICAGO, April  29, 2026  (GLOBE NEWSWIRE) &#8212; Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Emalex Biosciences (\u201cEmalex\u201d) today announced a definitive agreement for Teva to acquire Emalex, including its lead asset, ecopipam. The positive Phase 3 data of ecopipam in children with Tourette syndrome demonstrated statistically significant results on the study\u2019s primary efficacy endpoint, and the NDA submission is anticipated in 2H 2026.<\/p>\n<p align=\"justify\">Upon closing,\u00a0Teva will pay $700 million, and\u00a0Emalex\u2019s\u00a0shareholders\u00a0will be eligible to receive up to $200 million\u00a0based on\u00a0future\u00a0commercial\u00a0milestones\u00a0as well as royalties on\u00a0global\u00a0net sales\u00a0of ecopipam,\u00a0subject to regulatory approval.\u00a0<\/p>\n<p align=\"justify\">\n        <em>\u201cThis is a prime example of our Pivot to Growth strategy in action,\u00a0advancing\u00a0focused, capital<\/em>&#8211;<em>efficient\u00a0agreements\u00a0that expand our late<\/em>&#8211;<em>stage\u00a0innovative pipeline\u00a0and commercial portfolio,\u00a0while delivering on our unrelenting commitment to patients,\u201d\u00a0said Richard Francis, President and Chief Executive Officer of Teva.\u00a0\u201cThere is a real unmet need\u00a0in\u00a0Tourette syndrome, and families deserve\u00a0additional\u00a0options that can help manage symptoms while minimizing side effects.\u00a0With our deep\u00a0neuroscience\u00a0expertise,\u00a0we are well-positioned to advance this first-in-class investigational compound.\u201d<\/em>\u00a0<\/p>\n<p align=\"justify\">Ecopipam is a registration-ready selective dopamine D1 receptor antagonist for the treatment of pediatric Tourette syndrome. Currently approved Tourette syndrome medications act primarily on D2 receptors.<\/p>\n<p align=\"justify\">\n        <em>Eric Messner, Chief Executive Officer of\u00a0Emalex, said, \u201cThis moment reflects years of focused work to advance\u00a0a first-in-class therapy for patients with Tourette syndrome who need better options.\u00a0I\u2019m\u00a0deeply grateful to the\u00a0Emalex\u00a0team for the rigor and urgency\u00a0they\u2019ve\u00a0brought to this program, and to the patients, families, and investigators who made this progress possible. Teva\u2019s global scale and neuroscience leadership position\u00a0will help\u00a0ecopipam reach patients as quickly and broadly as possible, which is our goal.\u201d<\/em>\u00a0<\/p>\n<p align=\"justify\">Paragon Biosciences, which founded Emalex, creates, builds and funds innovative biology-based companies.<\/p>\n<p align=\"justify\">\n        <em>\u201cWe built Emalex around a clear patient need and advanced ecopipam to late-stage readiness with speed and precision. At Paragon, we take companies with proven science and a clear path to patients, then choose the fastest way to reach them. Teva brings the scale and neuroscience expertise to execute globally and accelerate access for patients,\u201d said Jeff Aronin, Paragon Biosciences CEO and Emalex Chairman.<\/em>\n      <\/p>\n<p align=\"left\">Teva is hosting its quarterly earnings call today, April 29, 2026, at 8:00 a.m. EDT, [<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p_Zsyr8gnpXPyp55loqB8d9mjmZw9VWknwnPTBeakF7qEii0j6MftfgnXPOTlxZJ1P2tc3bKwWvH8GrbWe5ZWsd6gIIAGnIVHerS9JIPIL8=\" rel=\"nofollow\" target=\"_blank\">link<\/a>] to share its Q1 2026 financial results. During that call, Teva will also discuss this acquisition.<\/p>\n<p align=\"left\">The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals, and is currently anticipated to close by Q3 2026. Teva will fund the upfront payment using cash on hand. Teva intends to mitigate the near-term margin dilutive impact of this acquisition and remains on track to meet its 2027 financial targets.\u00a0<\/p>\n<p align=\"left\">\n        <strong>About Tourette Syndrome<\/strong><br \/>\n        <br \/>Tourette syndrome is a chronic, childhood-onset neurodevelopmental disorder characterized by involuntary motor and vocal tics. It begins in childhood, often between 5 and 10 years old. For people living with Tourette syndrome, symptoms can be frequent, visible, and disruptive, affecting everyday life. Current treatment approaches can help, but many patients still do not get the level of control they need, or are limited by side effects, underscoring the need for additional options.<\/p>\n<p>In the\u00a0U.S.,\u00a0ecopipam has Orphan Drug designation for pediatric patients with Tourette syndrome.\u00a0Orphan Drug designation is reserved for patient populations of 200,000 or fewer.\u00a0A\u00a0substantial proportion\u00a0of people with TS\u00a0experience\u00a0moderate to severe symptoms. While\u00a0FDA-approved\u00a0and\u00a0off-label\u00a0medicines are used today, many patients and families still need\u00a0additional\u00a0options.\u00a0<\/p>\n<p>\n        <strong>About ecopipam\u00a0<\/strong><br \/>\n        <br \/>Ecopipam is a first-in-class investigational compound studied as a potential treatment for certain central nervous system disorders. It is designed to block dopamine signaling at the D1 receptor. The D1 receptor family includes subtypes D1 and D5. D1 receptor hypersensitivity may contribute to repetitive and compulsive behaviors associated with Tourette syndrome.<\/p>\n<p>Ecopipam has received Orphan Drug and Fast Track designations from the FDA for the treatment of pediatric patients with Tourette syndrome. Emalex announced the results of the Phase 3 Tourette Syndrome Study of ecopipam last year. The primary efficacy endpoint in the study was time to relapse for pediatric patients following randomization to ecopipam or placebo. The topline data showed statistical significance between ecopipam and placebo for the primary efficacy endpoint in pediatric patients (p = 0.0084). Ecopipam was generally well tolerated in the study and the most common adverse events related to ecopipam therapy were somnolence (10.2%), insomnia (7.4%), anxiety (6.0%), fatigue (5.6%), and headache (5.1%).<\/p>\n<p>\n        <strong>Advisors<\/strong><br \/>\n        <br \/>Evercore served as financial advisor and Faegre Drinker served as legal advisor to Teva. Centerview Partners LLC and PHCP, LLC served as financial advisors and Bradley Arant Boult Cummings, LLP, served as legal advisor to Emalex.<\/p>\n<p>\n        <strong>About Teva<\/strong>\u00a0<br \/>Teva\u00a0Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class\u00a0generics\u00a0business. For over 120 years, Teva\u2019s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines,\u00a0biosimilars\u00a0and pharmacy brands worldwide, Teva is dedicated to addressing patients\u2019 needs, now and in the future. At Teva, We Are All\u00a0In\u00a0For\u00a0Better Health. To learn more about how, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hUwKcYzhRo-GXRU-o3-zEWRa0YTKh1QDack7tHtHOyTghkLq-Z2xUCwE1kFKnH6yIaWd5_oMq13sXyYp5U11SoO-EqXPKQ5mcyQ4s_3iH2Y=\" rel=\"nofollow\" target=\"_blank\">www.tevapharm.com<\/a>.\u00a0<\/p>\n<p>\n        <strong>About Emalex<\/strong>\u00a0<br \/>Emalex Biosciences was created by Paragon Biosciences to develop new treatments for central nervous system disorders. The company is advancing a new class of therapy for patients with\u00a0Tourette syndrome\u00a0and other conditions with limited treatment options.\u00a0<\/p>\n<p>\n        <strong>About Paragon\u00a0Biosciences<\/strong>\u00a0<br \/>Paragon Biosciences, founded by Jeff Aronin, creates,\u00a0builds\u00a0and funds innovative biology-based companies.\u00a0Its portfolio companies advance scientific breakthroughs aimed at\u00a0addressing significant unmet medical needs.\u00a0Learn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rfyP7jvtTXebFlFiCvXvj6WKruqaWtCCb3w_W4KRKpm1v8DPCm5MMC4EspaZ9YG1hJQIMjVu3RdUjx8I7kLPxvLbFwTNjsXTfZf0zJuq9gNq2YIIW5yyD9homWJvz0Laoz_4pnlYC1mROg0LpqFPHTATWVq8snx5M0xzFhAfhu_M76KsNg7ae2349R5ALaXU1rdrKiMhlD6NTRFc2b_apxsDPlivhAFdKxLnO6gcsYa1f7c0s4nbFsd4ym7wgRBdmP7_EyyV8XAWp231fPRwgbzGiZeB3Xut6gqMfygyyZ9ap5ixp4luUZHTgc-0sL8kkHdTc-EGGoMXhzsyRpddux3K6fMyMXl8vkUxD6OH7_KCaSM-20k0PG80gaj_0yB4hRqzIrzoaDyFlvdZ87QYhNoLbrrDRMRMBy05dpODhIwioDsncNT68sr4ru5pwIX_OZlfTkDHnJJG2G84cI8P0z0yDJTpVZl1LHo4CPoY8uszLhaxMUvLWShqrN1vJYcZvTStn45ByWG7dq6yp8DKQGE-s_kuu0XQ-ujMrhFfnYwV6kPNEslyVv0FPp9maQgTXKrUJNX1gc8RItrNWJiECBJ89MweMM7HW36LDzOgNLONDytJE1R5pUKV5JDQJvQSICoWKer-hXRFsrXQzzm8ScmDcUr3wMH3YLmyUiTmbX5ed3CE5w2eo7EWUEYUFiP5Hpwc3tQ0e_-97s972pyQXfOO17HtVn1tws2Lf-lhcFwzcBe20r_76Td6oBVut6vYL-uUSw898JgtsX4mTaXDQb8Zk4bSaaKJHkZJ_WId-w6pSI75NWL8SSzabNLnOCaXo_VuIawe9S9Caq2IaGdvIq8uj6cgHa-zZpnB9wcbbztIz7xu1pZS2s-YHebl68bO0p0UFSfof4LaQ290fJUSMTDdTfAhTR_Yy6FcRWl5lbPbL8fnDJor8EOgxsXRsjg0mv77TUm-DC4XkKsyY3w1OM7-ljJImiGzcXRPB4yix6LDa7wZLYgag3rA22Leri1db66ZTAzsaoD8Dj484YV71YQx6gBJGRdwRlygzIP90PIxhHB_ycLZ5HmvUzBvGhS2P_tEVApc3lV4s_e4GTLvZoI1sQmTtS848yn-RfDOoqqrnY2VThApQjETSb2Smn8tvYYrqaX_01ufjmIvBDnYHhGlDjTAhM6ilkamOkXuOPBYeu-42pPx78oXr2VKMgIhtPDYLehSbmVDr5Fj15P_PWj8ECSFnxw0-KQJouGuqSNPrIP5nGa4O_SlU_wDrYOC\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.paragonbiosci.com<\/a>.\u00a0<\/p>\n<p>\n        <strong>Paragon Media Inquiries<\/strong>:<br \/>Sheridan Chaney<br \/>312.847.1323<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xi-vhUXiyRKausScE3WZT2Nb14sjhXXeEcRfscHmtdtmVe1NrZkNmtHEeEPvbWi02JDLctIPKo-E-XKVBf9VGuoa1B9WjnaUe12SxKgDJSE=\" rel=\"nofollow\" target=\"_blank\">sc@paragonbiosci.com<\/a><\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management\u2019s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause Teva\u2019s future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. All statements other than statements of historical fact are, or may be\u00a0deemed\u00a0to be, forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as \u201cshould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cdeveloping,\u201d \u201ctarget,\u201d \u201cmay,\u201d \u201cexpand,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve\u201d and other words and terms of similar meaning and expression in connection with any discussion of future performance. Important factors that could cause or contribute to such differences include risks and uncertainties relating to: the ability of the parties to consummate the proposed transaction in a timely manner or at all; the ability of the parties to satisfy the closing conditions under the merger agreement for the proposed transaction; potential delays in consummating the proposed transaction; our ability to successfully meet the payment obligations under the agreement with\u00a0Emalex; our ability to successfully develop, obtain regulatory approval for and commercialize ecopipam; our ability to successfully compete in the marketplace including our ability to develop and commercialize ecopipam and additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and other factors discussed in this press release and in\u00a0our\u00a0Annual Report on Form 10-K for the year ended December 31, 2025 and in our Quarterly Reports on Form 10-Q, including in the section captioned \u201cRisk Factors\u201d and Cautionary Note Regarding Forward Looking Statements.\u201d Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information\u00a0contained\u00a0herein, whether\u00a0as a result of\u00a0new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3ODY1OCM0MDIzODI5MzYjMjAwMzA3Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/YWJiOGU4NjItNDRmNS00MDMyLTgxODQtMGVlZWQ1ZGE5YmRiLTEwMTQ2NTAtMjAyNi0wNC0yOS1lbg==\/tiny\/Teva-Pharmaceutical-Industries.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ecopipam, Emalex\u2019s investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations.\u00a0 The\u00a0late-stage\u00a0program in\u00a0a\u00a0high-need, specialized\u00a0area of\u00a0neuroscience\u00a0expands\u00a0Teva\u2019s innovative medicines pipeline,\u00a0aligns with commercial strengths and supports both near-\u00a0and\u00a0long-term\u00a0growth.\u00a0 Upon closing, Emalex shareholders to receive $700 million in cash with the possibility of up to an additional $200 million in commercial milestone payments, as well as net sales-based royalties, subject to regulatory approval PARSIPPANY, N.J. and CHICAGO, April 29, 2026 (GLOBE NEWSWIRE) &#8212; Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Emalex Biosciences (\u201cEmalex\u201d) today announced a definitive agreement for Teva to acquire Emalex, including its lead asset, ecopipam. The positive Phase 3 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Teva to Acquire\u00a0Emalex\u00a0Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva\u2019s Pivot to Growth Strategy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-955781","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Teva to Acquire\u00a0Emalex\u00a0Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva\u2019s Pivot to Growth Strategy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teva to Acquire\u00a0Emalex\u00a0Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva\u2019s Pivot to Growth Strategy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Ecopipam, Emalex\u2019s investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations.\u00a0 The\u00a0late-stage\u00a0program in\u00a0a\u00a0high-need, specialized\u00a0area of\u00a0neuroscience\u00a0expands\u00a0Teva\u2019s innovative medicines pipeline,\u00a0aligns with commercial strengths and supports both near-\u00a0and\u00a0long-term\u00a0growth.\u00a0 Upon closing, Emalex shareholders to receive $700 million in cash with the possibility of up to an additional $200 million in commercial milestone payments, as well as net sales-based royalties, subject to regulatory approval PARSIPPANY, N.J. and CHICAGO, April 29, 2026 (GLOBE NEWSWIRE) &#8212; Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Emalex Biosciences (\u201cEmalex\u201d) today announced a definitive agreement for Teva to acquire Emalex, including its lead asset, ecopipam. The positive Phase 3 &hellip; Continue reading &quot;Teva to Acquire\u00a0Emalex\u00a0Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva\u2019s Pivot to Growth Strategy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-29T10:33:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3ODY1OCM0MDIzODI5MzYjMjAwMzA3Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Teva to Acquire\u00a0Emalex\u00a0Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva\u2019s Pivot to Growth Strategy\",\"datePublished\":\"2026-04-29T10:33:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\\\/\"},\"wordCount\":1440,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3ODY1OCM0MDIzODI5MzYjMjAwMzA3Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\\\/\",\"name\":\"Teva to Acquire\u00a0Emalex\u00a0Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva\u2019s Pivot to Growth Strategy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3ODY1OCM0MDIzODI5MzYjMjAwMzA3Nw==\",\"datePublished\":\"2026-04-29T10:33:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3ODY1OCM0MDIzODI5MzYjMjAwMzA3Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3ODY1OCM0MDIzODI5MzYjMjAwMzA3Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Teva to Acquire\u00a0Emalex\u00a0Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva\u2019s Pivot to Growth Strategy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Teva to Acquire\u00a0Emalex\u00a0Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva\u2019s Pivot to Growth Strategy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/","og_locale":"en_US","og_type":"article","og_title":"Teva to Acquire\u00a0Emalex\u00a0Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva\u2019s Pivot to Growth Strategy - Market Newsdesk","og_description":"Ecopipam, Emalex\u2019s investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations.\u00a0 The\u00a0late-stage\u00a0program in\u00a0a\u00a0high-need, specialized\u00a0area of\u00a0neuroscience\u00a0expands\u00a0Teva\u2019s innovative medicines pipeline,\u00a0aligns with commercial strengths and supports both near-\u00a0and\u00a0long-term\u00a0growth.\u00a0 Upon closing, Emalex shareholders to receive $700 million in cash with the possibility of up to an additional $200 million in commercial milestone payments, as well as net sales-based royalties, subject to regulatory approval PARSIPPANY, N.J. and CHICAGO, April 29, 2026 (GLOBE NEWSWIRE) &#8212; Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Emalex Biosciences (\u201cEmalex\u201d) today announced a definitive agreement for Teva to acquire Emalex, including its lead asset, ecopipam. The positive Phase 3 &hellip; Continue reading \"Teva to Acquire\u00a0Emalex\u00a0Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva\u2019s Pivot to Growth Strategy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-29T10:33:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3ODY1OCM0MDIzODI5MzYjMjAwMzA3Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Teva to Acquire\u00a0Emalex\u00a0Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva\u2019s Pivot to Growth Strategy","datePublished":"2026-04-29T10:33:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/"},"wordCount":1440,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3ODY1OCM0MDIzODI5MzYjMjAwMzA3Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/","name":"Teva to Acquire\u00a0Emalex\u00a0Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva\u2019s Pivot to Growth Strategy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3ODY1OCM0MDIzODI5MzYjMjAwMzA3Nw==","datePublished":"2026-04-29T10:33:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3ODY1OCM0MDIzODI5MzYjMjAwMzA3Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3ODY1OCM0MDIzODI5MzYjMjAwMzA3Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Teva to Acquire\u00a0Emalex\u00a0Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva\u2019s Pivot to Growth Strategy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=955781"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955781\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=955781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=955781"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=955781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}